Skip to main content

Advertisement

SpringerLink
Log in

Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bang UC, Hyldstrup L, Jensen JEB (2014) The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int 25:639–644. doi:10.1007/s00198-013-2470-y

    Article  CAS  PubMed  Google Scholar 

  2. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321

    Article  CAS  PubMed  Google Scholar 

  3. NPS Pharma Holdings Limited (2014) Preotact parathyroid hormone (rDNA). Summary of product characteristics. .http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000659/human_med_000984.jsp&mid=WC0b01ac058001d124. Accessed 5 March 2014.

  4. Eli Lilly Nederland B.V. (2013) Forsteo (teriparatide). Summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human_med_000798.jsp&mid=WC0b01ac058001d124. Accessed 2 April 2014.

  5. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J editors (2013) Cancer incidence in five continents, vol. X (electronic version). Lyon, International Agency for Research on Cancer. http://ci5.iarc.fr. Accessed on 13 February 2014

  6. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437. doi:10.1002/jbmr.1768

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Sørensen HT, Christensen T, Schlosser HK, Pedersen L, editors (2009) Use of medical databases in clinical epidemiology, second edition. http://kea.au.dk/download/Use_of_medical_databases_in_clinical_epidemiology_2nd_ed_472.pdf. Accessed 2 April 2014

Download references

Author information

Authors and Affiliations

  1. RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC, 27709-2194, USA

    E. B. Andrews, A. W. Gilsenan, K. D. Midkiff & D. H. Harris

Authors
  1. E. B. Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. W. Gilsenan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. D. Midkiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. H. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. B. Andrews.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrews, E.B., Gilsenan, A.W., Midkiff, K.D. et al. Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int 26, 1663–1664 (2015). https://doi.org/10.1007/s00198-014-3003-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-3003-z

Keywords

Search

Navigation